Plasmatech Biopharmaceuticals Inc PTBI shares ducked back 1.4% to $7.23 following the announcement of license deal for gene therapy in Fanconi anemia, CRISPR/Cas9-Based technology platform. Share volume was 103,000, compared to an all-day average of 629,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
